Literature DB >> 8319558

Thyromimetic effects of 3,5,3'-triiodothyronine sulfate in hypothyroid rats.

F Santini1, R E Hurd, B Lee, I J Chopra.   

Abstract

Several parameters of the effects of thyroid hormone were examined in hypothyroid thyroidectomized (Tx) rats treated with T3 sulfate (T3S) or T3 [0.46 (low dose) or 2.3 (high dose) nmol/day for 10 days, ip]. Tx rats showed a marked degree of growth retardation, which improved significantly after treatment with both doses of T3S and T3. The mean serum GH level was markedly reduced in Tx rats, and it improved significantly to similar levels after treatment with the high dose of T3S and the low dose of T3. Type I monodeiodinase (MD) activity was markedly reduced in liver and kidney tissues of Tx rats. It increased significantly in Tx rats treated with the high dose of T3S; the latter values were similar to those observed in Tx rats treated with the low dose of T3. Hepatic and renal type I MD activities increased to supranormal levels in Tx rats treated with the high dose of T3. Cardiac outer ring (5') monodeiodination of 3',5'-diiodothyronine to 3'-monoiodothyronine was also significantly reduced in Tx rats, but it improved significantly only after treatment with the high dose of T3. Type III 5-MD activity was significantly reduced in the cerebral cortex of Tx rats. It was restored to normal in Tx rats treated with the high dose of T3S and both doses of T3. Serum TSH, markedly elevated in Tx rats, was appreciably reduced only in rats treated with the high dose of T3. In another study, significant suppression of serum TSH was observed when Tx rats were treated with T3S (11.5 nmol/day) or T3 (2.3 nmol/day) for 3 days. We conclude that administration of T3S to hypothyroid rats produces thyromimetic effects, with a potency approximately one fifth that of T3.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8319558     DOI: 10.1210/endo.133.1.8319558

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  Optimal Thyroid Hormone Replacement.

Authors:  Jacqueline Jonklaas
Journal:  Endocr Rev       Date:  2022-03-09       Impact factor: 25.261

2.  Use of basal and TRH-stimulated plasma growth hormone concentrations to differentiate between primary hypothyroidism and nonthyroidal illness in dogs.

Authors:  Tera Pijnacker; Hans S Kooistra; Cathelijne F Vermeulen; Merel van der Vinne; Marrit Prins; Sara Galac; Jan A Mol
Journal:  J Vet Intern Med       Date:  2018-05-07       Impact factor: 3.333

Review 3.  Sustained Release T3 Therapy: Animal Models and Translational Applications.

Authors:  Thaer Idrees; John D Price; Thomas Piccariello; Antonio C Bianco
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-13       Impact factor: 5.555

4.  Treatment of Hypothyroid Patients With L-Thyroxine (L-T4) Plus Triiodothyronine Sulfate (T3S). A Phase II, Open-Label, Single Center, Parallel Groups Study on Therapeutic Efficacy and Tolerability.

Authors:  Ferruccio Santini; Giovanni Ceccarini; Caterina Pelosini; Monica Giannetti; Ilaria Ricco; Giorgia Querci; Enzo Grossi; Giorgio Saponati; Paolo Vitti
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-29       Impact factor: 5.555

5.  Effects of porcine reproductive and respiratory syndrome virus (PRRSV) on thyroid hormone metabolism in the late gestation fetus.

Authors:  Erin K Ison; Amber S Hopf-Jannasch; John C S Harding; J Alex Pasternak
Journal:  Vet Res       Date:  2022-09-30       Impact factor: 3.829

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.